Arie Belldegrun and David Chang steered Kite Pharma last year to a historic FDA approval and a $12 billion bear hug from Gilead Sciences. Now they’ve re-emerged with a new startup, Allogene, which has $300 million in backing and the rights to a CAR-T cell therapy program which is quite different from the one they brought to market with Kite.
With its cash haul, Allogene will take over U.S. development of UCART19, a cell therapy that Pfizer licensed in 2015. Pfizer has traded its rights for a 25 percent stake in Allogene. One year ago, Pfizer vice president of CAR-T… Read more »
UNDERWRITERS AND PARTNERS